Literature DB >> 16600414

A single transplantation of the islets can produce glycemic stability and reduction of basal insulin requirement.

Mariko Sassa1, Kazuhito Fukuda, Shimpei Fujimoto, Kentaro Toyoda, Yoshihito Fujita, Shinichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga, Hirofumi Noguchi, Hideo Nagata, Yukihide Yonekawa, Takeshi Ohara, Masahiko Okamoto, Koichi Tanaka, Yutaka Seino, Nobuya Inagaki, Yuichiro Yamada.   

Abstract

We investigated glycemic stability and insulin requirement 1 month after a single transplantation of the islets from non-heart-beating donors or a living donor. Overall blood glucose levels decreased immediately after transplantation. The M-value and mean amplitude of glycemic excursions (MAGE) decreased significantly from 53.0 (range, 8.9-91.0) to 4.2 (0.6-8.8, P<0.05) and from 8.5 mM (4.8-11.7) to 3.3 mM (2.0-4.5, P<0.05), respectively. The values after transplantation were lower than the first quartile of 102 type 2 diabetic control patients. The estimated HbA1c level decreased significantly from 7.9% (5.7-10.9) to 5.4% (4.7-5.9, P<0.05). The supplement of basal insulin decreased 43% from 0.31 units/kg/day (0.16-0.37) to 0.18 units/kg/day (0-0.22, P<0.05), while that of stimulated insulin did not decrease significantly, from 0.28 units/kg/day (0.13-0.51) to 0.21 units/kg/day (0-0.41). Thus, only one islet transplantation can be sufficient to attain metabolic stability, probably by effective supply of basal insulin secretion, sufficient to avoid life-threatening severe hypoglycemia and prevent or delay the progress of secondary complications of diabetes by decreasing the HbA1c level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600414     DOI: 10.1016/j.diabres.2006.01.012

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  1 in total

1.  Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes.

Authors:  Shinichi Matsumoto; Adrian Abalovich; Carlos Wechsler; Shaun Wynyard; Robert B Elliott
Journal:  EBioMedicine       Date:  2016-08-24       Impact factor: 8.143

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.